In a new job - May 25, 2022
ISD Immunotech appoints new CEO
ISD Immunotech has announced the appointment of Gert Bolwig as the company’s Chief Executive Officer. Gert Bolwig will be succeeding Ingelise Sunders who has acted as Executive Chairman. Ms. Saunders will continue as Chairman of the Board. “We are delighted to have Gert join our company,” says Ingelise Saunders, Chairman of the Board. “Gert is […]
Uncategorized - May 19, 2021
Personalized therapy for severe lupus
ISD Immunotech expects to finalize characterization of its STING antagonist lead candidate this year, aiming to develop the first personalized treatment for severe lupus patients. Systemic lupus erythematous (SLE) is a complex and hard-to-treat autoimmune disease with a high unmet medical need. It is the most common and most serious type of lupus, and is […]
Biotech Business - March 8, 2021
ISD Immunotech enters strategic research collaboration
ISD Immunotech has entered into a strategic research collaboration with Biogen. ISD and Biogen will work together to develop ISD’s lead compound, ISD 017, which is being developed to treat severe lupus – systemic lupus erythematosus (SLE). ISD 017 is a peptide therapeutic which is an inhibitor of the stimulator of interferon genes (STING) pathway. […]
